Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Following KarXT in Schizophrenia

24 Sep 2024

• By Elizabeth Cairns

red white and blue brain — • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

Related Content

Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint

20 Mar 2023

Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT

30 Oct 2023

Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field

30 Apr 2024

Cerevel Makes Progress, But Karuna Still One To Watch In Schizophrenia

06 Jul 2021

Newron Weighs Up Partners Or M&A As Excitement Grows Over Antipsychotic

19 Sep 2024

Neurocrine’s Phase II Results In Schizophrenia Mixed, But Enough To Move To Phase III

28 Aug 2024

Related Companies

Bristol Myers Squibb Company

Johnson & Johnson

Reviva Pharmaceuticals Holdings, Inc.

Neurocrine Biosciences, Inc.

Additional Topics

Clinical Trials Companies Evaluate Data Commercial Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.